Tachykinin receptors in chronic inflammatory lower airway diseases

Altamura, Maria Maddalena; Manzini, Stefano; Lecci, Alessandro

doi:10.1517/13543776.17.10.1241

Cited by 3 publications

(1 citation statement)

References 138 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In particular, NK1 antagonists reduced pulmonary neurogenic and non-neurogenic inflammation in several allergic and non-allergic models, while NK2 receptor antagonists showed the potential to reduce airway motor responses by a local action on smooth muscle tone, by preventing airway hyperreactivity and airway reflexes. Despite this preclinical evidence, clinical testing of NK2 selective or dual NK1/NK2 tachykinin antagonists has been largely disappointing [106].…”

Section: Gastrointestinal Diseases: Nepadutant and Ibodutantmentioning

confidence: 99%

Tachykinin receptor antagonists in clinical trials

Quartara

Altamura

Evangelista

et al. 2009

Expert Opinion on Investigational Drugs

Self Cite

View full text Add to dashboard Cite

Tachykinins (TKs) are small peptides widely distributed in the central and peripheral nervous systems where they act as neurotransmitters. Potent and selective TKs antagonists have been developed in the last 20 years and many efforts have been made to prove their efficacy in the treatment of various diseases. Herein the most prominent results in the clinical development are reported and discussed. For aprepitant, the only compound of this class to have been launched to date, results of clinical studies and postmarketing cost-effectiveness data for the treatment of chemotherapy-induced emesis are discussed. The field is still well active, as currently proof-of-concept studies for indications initially missed (i.e., depression) are ongoing and new targets are under investigation.

show abstract

Section: Gastrointestinal Diseases: Nepadutant and Ibodutantmentioning

confidence: 99%

Tachykinin receptor antagonists in clinical trials

Quartara

Altamura

Evangelista

et al. 2009

Expert Opinion on Investigational Drugs

Self Cite

View full text Add to dashboard Cite

show abstract

The role of neuro-immune cross-talk in the regulation of inflammation and remodelling in asthma

Veres

Rochlitzer

Braun

2009

Pharmacology & Therapeutics

View full text Add to dashboard Cite

Tachykinin NK2 receptor antagonists. A patent review (2006 – 2010)

Altamura

2011

Expert Opinion on Therapeutic Patents

View full text Add to dashboard Cite

Although there is still no tachykinin NK2 receptor antagonist approved for use in human therapy, research in the field is still proposing new compounds and possible uses. A number of candidates are being evaluated in Phase II clinical studies, in indications ranging from gastrointestinal disorders to inflammatory diseases. The results of these studies will indicate the role of tachykinin NK2 receptor antagonists in human therapy.

show abstract

Tachykinin receptors in chronic inflammatory lower airway diseases

Cited by 3 publications

References 138 publications

Tachykinin receptor antagonists in clinical trials

Tachykinin receptor antagonists in clinical trials

The role of neuro-immune cross-talk in the regulation of inflammation and remodelling in asthma

Tachykinin NK2 receptor antagonists. A patent review (2006 – 2010)

Contact Info

Product

Resources

About